Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis

Rheumatology

Volumn 47, Issue 12, 2008, Pages 1775-1779

  Choi, S T ^a   Kim, J H ^a   Kang, E J ^a   Lee, S W ^a   Park, M C ^a   Park, Y B ^a   Lee, S K ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Ankylosing spondylitis; Bone remodelling; Disease activity; Osteopontin

Indexed keywords

C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 6; MESSENGER RNA; OSTEOCALCIN; OSTEOPONTIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BONE METABOLISM; BONE REMODELING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENE EXPRESSION; HUMAN; INFLAMMATION; LIPID ANALYSIS; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; BONE REMODELING; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-6; MALE; MIDDLE AGED; OSTEOPONTIN; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 56649122122     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken385     Document Type: Article

References (31)

1. Bal A, Unlu E, Bahar G, Aydog E, Eksioglu E, Yorgancioglu R. Comparision of serum IL-1β, sIL-2R, IL-6, and TNF-α levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 2007;26:211-5.
2. Falkenvach A, Herold M. In ankylosing spondylitis serum interleukin-6 correlates with the degree of mobility restriction, but not with short-term changes in the variables for mobility. Rheumatol Int 1998;18:103-6.
3. Gratacos J, Collado A, Filella X et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and INF-gamma) in ankylosing spondylitis: A close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994;33:927-31.
4. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;369:1379-90.
5. Braun J, Khan MA, Sieper J. Enthesitis and ankylosis in spondyloarthropathy: What is the target of the immune response? Ann Rheum Dis 2000;59:985-94.
6. Karberg K, Zochling J, Sieper J, Felsenberg D, Braun J. Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophyte. J Rheumatol 2005;32:1290-8.
7. Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA 1986;83:8819-23.
8. Naldini A, Leali D, Pucci A et al. IL-1β medicates the proangiogenic activity of osteopontin-activated human monocytes. J Immunol 2006;177:4267-70.
9. Denhardt DT, Gou X. Osteopontin: A protein with diverse functions. FASEB J 1993;7:1475-82.
10. Weber GF. The metastasis gene osteopontin: A candidate target for cancer therapy. Biochim Biophys Acta 2001;1552:61-85.
11. O'Regan AW, Nau GJ, Chupp GL, Berman JS. Osteopontin (Eta-1) in cell-medicated immunity: Teaching an old dog new tricks. Immunol Today 2000;21: 475-8.
12. Giachelli CM, Lombardi D, Johnson RJ, Murray CE, Almeida M. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol 1998;152:353-8.
13. Weiss JM, Renkl AC, Maier CS et al. Osteopontin is involved in the initiation of cutaneous contact hypersensitivity by inducing Langerhans and dendritic cell migration to lymph nodes. J Exp Med 2001;194:1219-29.
14. Dhore CR, Cleutjens JP, Lutgens E et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001;21:1998-2003.
15. Bini A, Mann KG, Kudryk BJ, Schoen FJ. Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 1999;19:1852-61.
16. Chellaniah MA, Kizer N, Biswas R et al. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol Biol Cell 2003;14:173-89.
17. Denhardt DT, Noda M. Osteopontin expression and function: Role in bone remodeling. J Cell Biochem 1998;72(Suppl. 30-31):92-102.
18. Reinholt FP, Hultenby K, Oldberg A, Heinegard D. Osteopontin-a possible anchor of osteoclast to bone. Proc Natl Acad Sci USA 1990;87:4473-5.
19. Dodds RA, Connor JR, James IE et al. Human osteoclasts, not osteoblasts, deposit osteopontin onto resorption surfaces: An in vitro and ex vivo study of remodeling bone. J Bone Miner Res 1995;10:1666-80.
20. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996;271:509-12.
21. Jang JH, Kim JH. Improved cellular response of osteoblast cells using recombinant human osteopontin protein produced by Escherichia coli. Biotechnol Lett 2005;27:1767-70.
22. Zohar R, Cheifetz S, McCulloch CA, Sodek J. Analysis of intracellular osteopontin as a marker of osteoblastic cell differentiation and mesenchymal cell migration. Eur J Oral Sci 1998;106(Suppl. 1):401-7.
23. Moore MA, Gotoh Y, Rafidi K, Gerstenfeld LC. Characterization of a cDMA for chicken osteopontin: Expression during bone development, osteoblast differentiation, and tissue distribution. Biochemistry 1991;30:2501-8.
24. Ohshima S, Kobayashi H, Yamaguchi N et al. Expression of osteopontin at sites of bone erosion in a murine experimental arthritis model of collagen-induced arthritis: Possible involvement osteopontin in bone destruction in arthritis. Arthritis Rheum 2002;46:1094-101.
25. Yamamoto N, Sakai F, Kon S et al. Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. J Clin Invest 2003;112:181-8.
26. Xu G, Sun W, He D et al. Overexpression of osteopontin in rheumatoid synovial mononuclear cells is associated with joint inflammation, not with genetic polymorphism. J Rheumatol 2005;32:410-6.
27. Petrow PK, Hummel KM, Schedel J et al. Expression of osteopontin messenger RNA and protein in rheumatoid arthritis. Arthritis Rheum 2000;43:1597-605.
28. Mishima R, Takeshima F, Sawai T et al. High plasma osteopontin levels in patients with inflammatory bowel disease. J Clin Gastroenterol 2007;41:167-72.
29. Marzo-Ortega H, Emery P, McGonagle D. The concept of disease modification in spondyloarthropathy. J Rheumatol 2002;29:1583-5.
30. Landewe R, Wanders A, Mielants H, Dougados M, Van der Heijde D. Function in patients with ankylosing spondylitis is the resultante of patient-reported disease activity and radiographic damage of the spine [abstract]. Ann Rheum Dis 2004;63(Suppl. 1):88-9.
31. Van der Heijde D, Landewe R, Einstein S et al. Radiologic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324-31.